Stock Research: Alkem Laboratories

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

Alkem Laboratories

NSI:ALKEM INE540L01014
81
  • Value
    44
  • Growth
    76
  • Safety
    Safety
    69
  • Combined
    79
  • Sentiment
    58
  • 360° View
    360° View
    81
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Alkem Laboratories Ltd. is an India-based pharmaceutical company focused on developing, manufacturing, and selling pharmaceutical products. The company operates in pharmaceuticals, producing branded generics, generic drugs, active pharmaceutical ingredients (APIs), and nutraceuticals, with offerings in various medical fields including anti-infectives, cardiology, oncology, and more. It markets products in India and over 40 international markets, with the United States as a key focus. In the last fiscal year, the company had a market cap of $6958 millions, profits of $960 millions, and revenue of $1517 millions.

more

ANALYSIS: With an Obermatt 360° View of 81 (better than 81% compared with alternatives) for 2026, overall professional sentiment and financial characteristics for the stock Alkem Laboratories are very positive. The 360° View is based on consolidating four consolidated indicators, with all but one indicator above average for Alkem Laboratories. The consolidated Growth Rank has a good rank of 76, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. This means that growth is higher than for 76% of competitors in the same industry. The consolidated Safety Rank at 69 means that the company has a financing structure that is safer than 69% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. Finally, the consolidated Sentiment Rank has a good rank of 58, which means that professional investors are more optimistic about the stock than for 58% of alternative investment opportunities. But the consolidated Value Rank is less desirable at 44, meaning that the share price of Alkem Laboratories is on the higher side compared with indicators such as revenues, profits, and invested capital. This means the stock price is higher than for 56% of alternative stocks in the same industry. ...read more

more
Index
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 13-Mar-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
44 61 51 71
Growth
76 25 97 37
Safety
Safety
69 46 42 57
Sentiment
58 27 80 26
360° View
360° View
81 22 88 47
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
28 15 25 62
Opinions Change
72 31 50 13
Pro Holdings
n/a 42 83 20
Market Pulse
52 54 83 67
Sentiment
58 27 80 26
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
44 61 51 71
Growth
76 25 97 37
Safety Safety
69 46 42 57
Combined
79 28 85 61
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
30 48 50 59
Price vs. Earnings (P/E)
40 58 38 64
Price vs. Book (P/B)
30 45 44 54
Dividend Yield
63 56 47 62
Value
44 61 51 71
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
61 48 44 39
Profit Growth
66 47 86 34
Capital Growth
77 16 79 73
Stock Returns
63 35 91 47
Growth
76 25 97 37
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
57 44 48 44
Refinancing
58 60 62 64
Liquidity
64 47 37 57
Safety Safety
69 46 42 57

Similar Stocks

Discover high‑ranked alternatives to Alkem Laboratories and broaden your portfolio horizons.

Kalbe Farma

JKT:KLBF
Country: Indonesia
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

SBI Life Insurance

NSI:SBILIFE
Country: India
Industry: Life & Health Insurance
Size: Large
Full Stock Analysis

Mega Lifesciences

SET:MEGA
Country: Thailand
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

CESC

NSI:CESC
Country: India
Industry: Electric Utilities
Size: Medium
Full Stock Analysis

Frequently Asked
Questions

This stock offers a high growth opportunity with safe financing and positive sentiment. It is typically expensive (low Value Rank), as investors pay a premium for high performance. It is for growth-focused investors comfortable paying a premium for a stock with strong future momentum.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing: